Market revenue in 2023 | USD 0.8 million |
Market revenue in 2030 | USD 2.7 million |
Growth rate | 18.6% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 62.5% in 2023. Horizon Databook has segmented the Norway plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The growing popularity of gene therapy and rising burden of cancer cases are the primary factors driving growth of the market in the region. Cancer is the second-leading cause of deaths globally with 19.3 million new cases and 10.0 million cancer deaths in 2020.
In Norway, where breast cancer is still the most prevalent type of cancer, followed by colorectal cancer and lung cancer, women comprised 46.0% of all new cases. The incidence of cancer cases and age-standardized incidence rates for majority of malignancies are rising, according to the most recent report from the Cancer Registry of Norway.
This pattern predicts that Norway's already significant cancer burden would continue to rise, putting more strain on the healthcare system in terms of screening & treatment. This would increase the demand for therapies further driving pDNA contract manufacturing market.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Norway plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account